Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K7 | O14733 | 1/20 | 0.37 |
| ▸ | CDC25A | P30304 | 1/20 | 0.37 |
| ▸ | CDC25B | P30305 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.35 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 4/20 | 0.33 |
| ▸ | S100A4 | P26447 | 2/20 | 0.33 |
| ▸ | MGLL | Q99685 | 1/20 | 0.33 |
| ▸ | ANPEP | P15144 | 1/20 | 0.33 |
| ▸ | DPP4 | P27487 | 1/20 | 0.33 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17033194 | 0.79 | CDC25B (0.39) | MAP2K7CDC25ACDC25BS100A4ALDH1A1 | |
| SCHEMBL18311506 | 0.77 | PDCD1 (0.47) | MAP2K7CDC25ACDC25BCYP2D6GABRA1 | |
| SCHEMBL17039134 | 0.75 | CYP2D6 (0.39) | CYP2D6GABRA1GABRB2LMNAMGLL | |
| SCHEMBL17034471 | 0.75 | HTR1A (0.39) | CYP2D6GABRA1GABRB2LMNAMGLL | |
| SCHEMBL18649201 | 0.75 | MAP2K7 (0.36) | MAP2K7CDC25ACDC25BGABRA1GABRB2 | |
| SCHEMBL17033191 | 0.72 | HDAC4 (0.43) | MAP2K7CDC25ACDC25BCYP2D6GABRA1 | |
| SCHEMBL13895541 | 0.70 | GABRA1 (0.43) | GABRA1GABRB2LMNAALDH1A1GAA | |
| SCHEMBL5190741 | 0.68 | GABRA1 (0.41) | GABRA1GABRB2LMNAALDH1A1NPC1 | |
| SCHEMBL22342193 | 0.66 | CSNK2A2 (0.42) | MAP2K7CDC25ACDC25BCYP2D6GABRA1 | |
| SCHEMBL9190050 | 0.66 | GABRA1 (0.52) | GABRA1GABRB2MGLLPDK2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9732103-B2 | Carbamate, ester, and ketone compounds for treatment of complement mediated disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2017-08-15 | — | — | US | disclosed |
| US-9695205-B2 | Amide compounds for treatment of complement mediated disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2017-07-04 | — | — | US | disclosed |
| US-20160362398-A1 | AMIDE COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2016-12-15 | — | — | US | disclosed |
| US-20150239895-A1 | Aryl, Heteroaryl, and Heterocyclic Compounds for Treatment of Complement Mediated Disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2015-08-27 | — | — | US | disclosed |
| US-20150239893-A1 | Amide Compounds for Treatment of Complement Mediated Disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2015-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160362398-A1 | AMIDE COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | CFD, TFPI, CFH | MAP2K7 3430/4885CDC25A 2595/4885CDC25B 2332/4885 |
| US-20150239895-A1 | Aryl, Heteroaryl, and Heterocyclic Compounds for Treatment of Complement Mediated Disorders | TFPI, CFD, F3 | MAP2K7 1462/4885CDC25A 2835/4885CDC25B 2406/4885 |
| US-20150239893-A1 | Amide Compounds for Treatment of Complement Mediated Disorders | CFD, TFPI, C9 | MAP2K7 3628/4885CDC25A 1800/4885CDC25B 1606/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.